As anticipation builds over the arrival of safe and effective Covid-19 vaccines, a growing challenge for the various manufacturers is to plot a successful path for distribution. The issues range from ensuring vaccines are stored at necessary temperatures and expanding manufacturing capacity to preventing theft and making deliveries in countries where infrastructure is lacking. One of the people responsible for piecing together such public health jigsaw puzzles is Remo Colarusso, vice president for supply chain responsibilities at Janssen, a Johnson & Johnson (JNJ) subsidiary that is among the companies racing to develop a vaccine. We spoke with him about the effort and how the company is approaching the task. This is an edited version of our conversation.
Before we get into distribution, what’s the status of your vaccine?
About the Author Reprints
